Hyperfine, creator of the MRI device, Swoop, has received U.S. FDA 510(k) clearance for its new image reconstruction technology, which utilizes deep learning capabilities. Hyperfine’s portable Swoop system is designed to overcome current MRI limitations—resulting from size, fixed location, cost, and staff training requirements—by rethinking MRI design, along with smart computing.

“Improved image quality through artificial intelligence, paired with the lower cost and bedside capabilities of Swoop, are enabling greater access to high-quality MR imaging for patients, regardless of income, resources, or location,” says Dave Scott, president and chief executive officer of Hyperfine.

For clinicians, better image quality can support more accurate and faster diagnoses. For patients, more rapid diagnosis and treatment can support shorter hospital stays and an improved overall healthcare experience.

“Swoop is already a game-changer in terms of its ability to provide MR imaging at a patient’s bedside,” says Fady Charbel, MD, FAANS, FACS, head of the department of Neurosurgery at the University of Illinois of Chicago. “With the integration of deep learning-based image reconstruction, clinicians can now visualize anatomy and pathology more clearly and with increased confidence enabling diagnosis in a more expeditious fashion, critical for the treatment of acute neurological conditions.”

In January, Hyperfine received FDA clearance for its advanced artificial intelligence application, which measures brain structure and pathology in images.